Journal article
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
TA Muranen, S Khan, R Fagerholm, K Aittomäki, JM Cunningham, J Dennis, G Leslie, L McGuffog, MT Parsons, J Simard, S Slager, P Soucy, DF Easton, M Tischkowitz, AB Spurdle, RK Schmutzler, B Wappenschmidt, E Hahnen, MJ Hooning, CF Singer Show all
Npj Breast Cancer | Published : 2020
Abstract
Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients, the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a hazard ratio 4.37 (95% confidence interval 3.03–6.30, P = 3.1 × 10−9). Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. The CIMBA data management and data analysis were supported by Cancer Research-UK grants C12292/A20861 and C12292/A11174. Genotyping for the OncoArray was funded by the government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministere de l'Economie, de la Science et de l'Innovation du Quebec through Genome Quebec, the Quebec Breast Cancer Foundation for the PERSPECTIVE project, the US National Institutes of Health (NIH; 1 U19 CA 148065 for the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract HHSN268201200008I), Cancer Research UK (C1287/A16563), the Odense University Hospital Research Foundation (Denmark), the National R&D Program for Cancer Control-Ministry of Health and Welfare (Republic of Korea; 1420190), the Italian Association for Cancer Research (AIRC; IG16933), the Breast Cancer Research Foundation, the National Health and Medical Research Council (Australia) and German Cancer Aid (110837). Detailed acknowledgements appear in the Supplementary note.